The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non‐muscle‐invasive bladder cancer. (31st January 2018)

• Record Type: Journal Article
• Authors: Bosschieter, Judith; van Moorselaar, R. Jeroen A.; Vis, André N.; van Ginkel, Tessa; Lissenberg‐Witte, Birgit I.; Beckers, Goedele M.A.; Nieuwenhuijzen, Jakko A.
• Is Part Of: BJU international. Volume 122:Number 4(2018)
• Page Start: 571
• Page End: 575
• Publication Date: 2018-01-31
• Subjects: intravesical chemotherapy -- mitomycin C -- urinary bladder neoplasms; Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.14124
• Languages: English
• ISSNs: 1464-4096

Abstract

Abstract : Objective: To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods: All patients with NMIBC who were enrolled in a prospective trial between 1998 and 2003, and treated with an early mitomycin C instillation (on the day of TURBT or 1 day later), were selected. Statistical analysis was performed with Kaplan–Meier curves and multivariable Cox regression. Results: Administering an instillation of mitomycin C on the day of TURBT or 1 day later did not show a statistically significant difference in time to recurrence in a univariable model (log‐rank P = 0.99). After correcting for the number of scheduled adjuvant instillations, no statistically significant difference could be detected either: hazard ratio 1.05 (95% confidence interval 0.81–1.35, P = 0.74). Conclusion: These data do not support the hypothesis that a very early instillation (on the day of TURBT) of mitomycin C decreases the risk of recurrence as compared with an early instillation (1 day after TURBT).